MARKET REPORT

Acne Vulgaris Forecast in 15 Major Markets 2016-2026

BioPortfolio

Life Science Healthcare and Pharmaceutical Market Research and Corporate Data

Acne Vulgaris Forecast in 15 Major Markets 2016-2026

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.
We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acne Vulgaris Forecast in 15 Major Markets 2016-2026

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acne Vulgaris in 15 Major Markets

Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and occasionally, scars. It can affect the face, anterior chest and upper back.

This report provides the current prevalent population for Acne Vulgaris across 15 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Turkey, Poland, Australia, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Acne Vulgaris have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Acne Vulgaris include:

• Underlying hormone imbalance

• Puberty

• Family history

• Skin scarring

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Acne Vulgaris's market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris's prevalent population.

• Identify sub-populations within Acne Vulgaris which require treatment.

• Gain an understanding of the specific markets that have the largest number of Acne Vulgaris disease patients.

Additional Details

Publisher : Black Swan Analysis
Reference : ACVG00111216

Number of Pages : 72
Report Format : PDF
Publisher Information :

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we've seen what works and what doesn't and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today's complex healthcare marketplace.

The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.

We have the capability to provide an immediate and 'hands-on' approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.

The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.

Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Table Of Contents for Acne Vulgaris Forecast in 15 Major Markets 2016-2026 [Report Updated: 01-12-2016]

- Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acne Vulgaris in 15 Major MarketsAcne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and occasionally, scars. It can affect the face, anterior chest and upper back.This report provides the current prevalent population for Acne Vulgaris across 15 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Turkey, Poland, Australia, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Acne Vulgaris have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.Main symptoms and co-morbidities for Acne Vulgaris include:• Underlying hormone imbalance• Puberty• Family history• Skin scarringThis report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report. Reason to buy• Able to quantify patient populations in global Acne Vulgaris's market to target the development of future products, pricing strategies and launch plans. • Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.• Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris's prevalent population.• Identify sub-populations within Acne Vulgaris which require treatment.• Gain an understanding of the specific markets that have the largest number of Acne Vulgaris disease patients.

List Of Tables in Acne Vulgaris Forecast in 15 Major Markets 2016-2026 [Report Updated: 01-12-2016]

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acne Vulgaris in 15 Major Markets

Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although acne can develop at any age, it most commonly affects adolescents and is triggered by the overproduction of sebum in the sebaceous glands. Acne vulgaris is characterised by presence of comedones, papules, pustules, cysts, nodules and occasionally, scars. It can affect the face, anterior chest and upper back.

This report provides the current prevalent population for Acne Vulgaris across 15 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Turkey, Poland, Australia, Japan, China, Brazil and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Acne Vulgaris have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Acne Vulgaris include:

• Underlying hormone imbalance

• Puberty

• Family history

• Skin scarring

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Acne Vulgaris's market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of Acne Vulgaris and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on Acne Vulgaris's prevalent population.

• Identify sub-populations within Acne Vulgaris which require treatment.

• Gain an understanding of the specific markets that have the largest number of Acne Vulgaris disease patients.

List Of Figures, Charts and Diagrams in Acne Vulgaris Forecast in 15 Major Markets 2016-2026 [Report Updated: 01-12-2016]

See List of Tables for the Figures

How to Buy...

Acne Vulgaris Forecast in 15 Major Markets 2016-2026 [Report Updated: 01-12-2016]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/81364

Option 2 - Request a Proforma Invoice
Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com
or **Fax** it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ....
Job Title: ....
Your Email: ....
Your Contact Phone: ....
Company Name: ....
Address: ....
....
Post/Zip Code: ....
Country: ....
P.O. Number: ....
Any Other Instructions: ....
....

Pricing Options: (please tick one)
○ **$6100** | Single User Price
○ **$10500** | Site License Price
○ **$17000** | Enterprise License Price

Payment Options: (please tick one)
○ **Online Credit Card** (we will email you the invoice with a payment link)
○ **Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature: ....

Option 3 - Phone Us on +44 (0)1300 321501
We will be delighted to give you our personal attention.